Last $3.37 USD
Change Today +0.11 / 3.37%
Volume 25.7K
UPI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

uroplasty inc (UPI) Snapshot

Open
$3.29
Previous Close
$3.26
Day High
$3.48
Day Low
$3.29
52 Week High
01/24/14 - $5.40
52 Week Low
07/12/13 - $1.69
Market Cap
72.9M
Average Volume 10 Days
58.4K
EPS TTM
$-0.25
Shares Outstanding
21.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UROPLASTY INC (UPI)

Related News

No related news articles were found.

uroplasty inc (UPI) Related Businessweek News

No Related Businessweek News Found

uroplasty inc (UPI) Details

Uroplasty, Inc., a medical device company, engages in the development, manufacture, and marketing of products for the treatment of voiding dysfunctions. The company principally offers Urgent PC Neuromodulation system, a minimally-invasive, neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder (OAB) and the associated symptoms of urinary urgency, urinary frequency, and urge incontinence; and Macroplastique, a urethral bulking agent for the treatment of adult female stress urinary incontinence due to intrinsic sphincter deficiency, as well as for the treatment of male stress incontinence, fecal incontinence, vocal cord rehabilitation, and vesicoureteral reflux. It also provides PTQ Implants, which offers a minimally-invasive, soft-textured permanent implant for treatment of fecal incontinence; and VOX Implants, a silicone elastomer bulking material for vocal cord rehabilitation applications, as well as engages in the distribution of wound care products. The company sells its products primarily to urologists, urogynecologists, and gynecologists through a direct sales organization in the United States, the United Kingdom, and the Netherlands, as well as through distributors in other markets. Uroplasty, Inc. was incorporated in 1992 and is headquartered in Minnetonka, Minnesota.

96 Employees
Last Reported Date: 07/23/13
Founded in 1992

uroplasty inc (UPI) Top Compensated Officers

Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $214.0K
Vice President of Corporate Development
Total Annual Compensation: $195.1K
Vice President of Global Marketing
Total Annual Compensation: $205.1K
Compensation as of Fiscal Year 2013.

uroplasty inc (UPI) Key Developments

Uroplasty, Inc. Names Daniel P. Merz as Vice President of Healthcare Affairs

Uroplasty, Inc. announced that Daniel P. Merz has joined the company as Vice President of Healthcare Affairs. In this role, he will oversee Uroplasty's strategy to educate payors and providers of the efficiency, effectiveness and overall value of the company's products. He joins Uroplasty with fifteen years of medical device experience, specifically in driving commercial success through enhanced reimbursement, novel clinical research and efficient regulatory clearances. Mr. Merz has a deep background in strategic planning, process reengineering and successful influence on medical organizations and reimbursement policy. Most recently, he directed the clinical affairs program at St. Jude Medical in Plymouth, Minnesota, where he was accountable for the global trans-catheter and surgical heart valve clinical programs. Prior to that, he oversaw the clinical and regulatory team supporting the global BPH capital equipment business in Minnesota and California for American Medical Systems.

Uroplasty, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 08:30 AM

Uroplasty, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 08:30 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Brett A. Reynolds, Chief Financial Officer and Senior Vice President, Robert E. Kill, Chief Executive Officer, President and Director.

Uroplasty, Inc. Appoints Suranjan Roychowdhury as Vice President of Research & Development and Clinical Affairs

Uroplasty, Inc. announced that it has appointed Dr. Suranjan Roychowdhury as Vice President of Research & Development and Clinical Affairs. This newly created position within the Uroplasty organization was established to provide focus, oversight and guidance to the company's product pipeline and clinical trials. Dr. Roychowdhury joins Uroplasty with more than 20 years of functional leadership experience and success in the development and commercialization of implantable and disposable medical devices. Most recently, Dr. Roychowdhury was with Vascular Solutions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UPI:US $3.37 USD +0.11

UPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $133.92 USD +2.46
Boston Scientific Corp $13.65 USD +0.15
Coloplast A/S kr418.20 DKK +6.00
InspireMD Inc $2.46 USD +0.10
Salix Pharmaceuticals Ltd $101.06 USD +0.40
View Industry Companies
 

Industry Analysis

UPI

Industry Average

Valuation UPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROPLASTY INC, please visit www.uroplasty.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.